
Chandra Bhagat Pharma Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Chandra Bhagat Pharma Limited's successfully completed its Initial Public Offering and commenced trading on Feb 14, 2020 at the BSE exchange. The company raised 20,00,000 Shares through this public offering, comprising TBD in fresh capital.
The IPO was priced within the band of ₹51 to ₹51, with minimum application lots of 2000 shares. The offering attracted significant investor interest during its subscription period from Jan 31, 2020 to Feb 06, 2020.
Share allotment was finalized on Feb 12, 2020, distributing equity to successful applicants. The stock's subsequent listing marked a significant milestone in the company's corporate history, providing public market liquidity to shareholders.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Chandra Bhagat Pharma Limited, established in 2003, is engaged in marketing lifesaving medicines in India across therapeutic areas such as cardiovascular care, cancer treatment, antibiotics, hormones, anesthesia, pediatrics, nephrology, antiviral, antifungal, and neurology. The company operates under its own brand with the support of an in-house sales team and distribution network that supplies healthcare centers and hospitals, while also dealing in specialty chemicals. In addition to finished formulations, it imports, supplies, and undertakes indenting of active pharmaceutical ingredients and intermediates, and holds FDA approval to manufacture formulations through contract manufacturers. Its storage facilities are located on a leased basis in Bhiwandi, Thane, Maharashtra, and the company also exports pharmaceutical products to international markets including DR Congo, Bolivia, and the Philippines.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Business model focused on customer needs and orders
- Strong ties with multinational companies (MNCs)
- Offers a wide range of products, including APIs and pharmaceuticals
- Has contract manufacturing services
- Operates in both Indian and global markets
NA
- Mr. Hemant Chandravadan Bhagat,
- Mr. Pranav Hemant Bhagat
Chandra Bhagat Pharma Limited
Link Intime India Private Limited
